Anti-FGF-2 nanobody inhibits rat corneal angiogenesis induced by alkali burn / 中国临床药理学与治疗学
Chinese Journal of Clinical Pharmacology and Therapeutics
;
(12): 609-615, 2021.
Article
in Chinese
| WPRIM
| ID: wpr-1015010
ABSTRACT
AIM:
To investigate the possible use of anti-FGF-2 nanobody for the treatment of pathological neovascularization.METHODS:
SD rats were divided into a sham operation group, a control group (3 mm diameter circular filter paper soaked with 1 mol/L NaOH solution was applied to the central part of the cornea of rats for 30 s to prepare the rat model of alkali-burn angiogenesis) and a treatment group (treated with a drop of 3 mg/mL anti-FGF-2 nanobody 7 days after the operation. Repeat application 3x/day for 14 days). Corneal angiogenesis was measured by stereoscopic microscopy and CD31 immunohistochemical staining. The mRNA and protein expression levels of VEGF and FGF-2 were detected by quantitative fluorescence PCR (qPCR), enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry.RESULTS:
(1) Blood vessel The area of the treatment group was significantly reduced compared with the model group, and the vascular lumen was narrower (P0.05); (3) Expression levels of VEGF mRNA and protein The treatment group was significantly higher than the model group (P<0.05). In addition, the expression of VEGF also increased significantly in the continuous administration of the sham operation group.CONCLUSION:
Anti-FGF-2 nanobody can be used for the treatment of angiogenesis. However, the expressions of VEGF will compensatorily increase after blocking FGF-2 in normal or pathological rats.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Chinese Journal of Clinical Pharmacology and Therapeutics
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS